NRAS and myeloid leukemia: The activity of compound 3 was tested on KRAS (G12C, G12D, G12V, and G13D) isoforms and two NRAS-mutated cell lines (significantly found in myeloid leukemia and myeloma [158]); compound 3 demonstrated significant cytotoxic activity for all the isoforms, with the most potent IC50 value being observed in the NRAS (Q61K) isoform [151].